Related Experiment Video
Updated: Jun 23, 2026

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
Published on: August 28, 2021
Prolonged dexmedetomidine infusions in critically ill infants and children
Pamela D Reiter1, Molli Pietras, Emily L Dobyns
1Department of Pharmacy, Center for Pediatric Medicine, The Children's Hospital, 13123 East 16th Ave, Denver, USA. reiter.pam@tchden.org
Insights
Prolonged infusions of dexmedetomidine (DEX) in critically ill children reduced the need for other sedatives and analgesics. DEX was generally well tolerated, with a slight decrease in heart rate upon initiation.
Area of Science:
- Pediatric Critical Care Medicine
- Pharmacology
- Intensive Care Unit Management
Background:
- Prolonged sedation and analgesia are common in critically ill pediatric patients.
- Dexmedetomidine (DEX) is an alpha-2 adrenergic agonist used for sedation and analgesia.
- Limited data exist on the long-term use of DEX in pediatric intensive care settings.
Purpose of the Study:
- To evaluate the institutional experience with prolonged dexmedetomidine (DEX) infusions in critically ill infants and children.
- To assess the efficacy and tolerability of DEX in this population.
Main Methods:
- Retrospective chart review of pediatric patients (up to 18 years) receiving DEX infusions for over 24 hours.
- Data collected included DEX dosing, rationale for use, sedation scores, vital signs, and conventional analgesic/sedative requirements.
- Analysis focused on changes in sedation scores, heart rate, blood pressure, and concomitant medication use.
Main Results:
- Twenty-nine patients received DEX for a median of 76 hours (range 32-378 hours).
- Common reasons for DEX use included facilitating extubation and reducing opioid/benzodiazepine use.
- Sedation scores remained stable, and conventional analgesic/sedative use decreased.
- A transient, statistically significant reduction in heart rate was observed upon initiation, but blood pressure remained unchanged.
Conclusions:
- Prolonged dexmedetomidine infusions are effective in reducing the need for other sedatives and analgesics in critically ill children.
- DEX was generally well tolerated, with a manageable decrease in heart rate.
- Further research may clarify the clinical significance of heart rate changes with prolonged DEX use.
Objective:
To present our institutional experience with prolonged dexmedetomidine (DEX) infusions in critically ill infants and children.
Design:
Retrospective medical chart review between January 1, 2007 and December 1, 2007.
Setting:
Tertiary care pediatric teaching hospital.
Participants:
Infants and children (up to 18 years of age) who received DEX for a duration greater than 24 hours.
Main Outcome Measures:
DEX dosing schema and rationale for use. Indices describing DEX efficacy and tolerability including change in patient-specific sedation scores, change in blood pressure and heart rate, and change in conventional analgesia and sedation requirements.
Results:
Twenty-nine patients (age 5.32 +/- 6.1 y) were evaluated. DEX therapy was initiated at 0.36 +/- 0.16 mcg/kg/hour. One-third of patients received a loading dose (0.5-1 mcg/kg) prior to the start of the infusion. Duration of DEX therapy was 110 +/- 83 hours (range 32-378 hours; median 76 hours). Rationale for adding DEX to sedation regimens included: intent to extubate (n=12), intent to reduce benzodiazepine and opioid use (n=10), exclusive continuous sedation (n=5) and management of drug withdrawal (n=2). Sedation scores remained stable during DEX therapy. Use of conventional analgesia and sedation was generally reduced while receiving DEX. Initiation of therapy was associated with a transient, yet statistically significant reduction in HR (from 120 +/- 28 bpm to 107 +/-N 27 bpm) (P = 0.002), but without a change in blood pressure.
Conclusions:
Prolonged DEX infusions were associated with a reduction in concomitant analgesia and sedation medications. DEX was well tolerated with the exception of heart rate, which decreased during the initiation of therapy but may not represent a clinically significant reduction.
Related Concept Videos
Parenteral Anesthetics: Overview
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Skeletal Muscle Relaxants: Adverse Effects
Unlike...